XHKG
8622
Market cap11mUSD
Oct 09, Last price
0.17HKD
1D
-5.17%
1Q
-7.30%
IPO
-61.18%
Name
Huakang Biomedical Holdings Co Ltd
Chart & performance
P/E
—
P/S
2.57
EPS
—
Div yield, %
—
Shrs. gr., 5y
4.62%
Rev. gr., 5y
5.18%
Revenues
28m
+11.53%
Net income
-5m
L+20.39%
CFO
-2m
L-27.82%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Huakang Biomedical Holdings Company Limited operates as an investment holding firm, primarily dedicated to the research, development, manufacturing, marketing, and distribution of in-vitro diagnostic (IVD) reagents within the People's Republic of China. Its comprehensive product portfolio encompasses IVD reagents designed for assessing male and female fertility, detecting parasite antibodies, and identifying the Epstein-Barr virus. Additionally, the company provides auxiliary reproductive supplies and equipment, alongside a range of healthcare products and nutritional supplements marketed under its 'Nutronic' brand, which are sold through both digital and physical platforms. Products are distributed directly to hospitals and medical institutions, as well as through a network of third-party distributors. The company was founded in 1992 and maintains its headquarters in Wan Chai, Hong Kong.
Key people
Yujing Zhang
Executive Chairman of the Board · since 2025
Chunguang Zhang
Chief Executive Officer, Executive Director · since 2017
Yim Yang Chang
Vice Chairman of the Board, Director of Shenzhen Huakang Bio-Medical Engineering Limited
Jianhua Fu
Chief Technology Officer, Deputy General Manager of Shenzhen Huakang
Chief Financial Officer, Compliance Officer, Executive Director · since 2017
Shuguang Zhang
Executive Chairman of the Board · since 2017
Lai Ki Chau
Company Secretary, Financial Controller · since 2017
Su Bu
Non-Executive Director · since 2024
Ming Xu
Non-Executive Director · since 2024
Kwok Fai Chow
Independent Non-Executive Director
Wing Tak Tsui
Independent Non-Executive Director · since 2025
Yachun Wang
Non-Executive Independent Director · since 2025
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||